4.7 Article

Estimated pulse wave velocity improves risk stratification for all-cause mortality in patients with COVID-19

期刊

SCIENTIFIC REPORTS
卷 11, 期 1, 页码 -

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41598-021-99050-0

关键词

-

资金

  1. European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme [759248]
  2. German Research Foundation DFG [SFB834, 75732319]
  3. Hellenic Cardiology Society
  4. Deutsche Herzstiftung (German Heart Foundation)
  5. National Institute for Health Research (NIHR) Clinical Lectureship [CL-2017-01-004]
  6. NIHR Academic Clinical Fellowship [ACF-2018-01-004]
  7. British Medical Association Foundation
  8. Wellcome Trust [211153/Z/18/Z]
  9. Onassis Foundation under the special grant & support program for scholars' association members [R ZP 001/2019-2020]

向作者/读者索取更多资源

Accurate risk stratification is crucial in guiding therapeutic strategies for COVID-19 patients. This study found that estimated pulse wave velocity (ePWV), a marker of arterial stiffness, provided additional prognostic value beyond established risk factors and scores in risk stratification of hospitalized COVID-19 patients. The optimal prognostic ePWV value was 13.0 m/s, suggesting its potential as a clinical tool for refining risk stratification in these patients.
Accurate risk stratification in COVID-19 patients consists a major clinical need to guide therapeutic strategies. We sought to evaluate the prognostic role of estimated pulse wave velocity (ePWV), a marker of arterial stiffness which reflects overall arterial integrity and aging, in risk stratification of hospitalized patients with COVID-19. This retrospective, longitudinal cohort study, analyzed a total population of 1671 subjects consisting of 737 hospitalized COVID-19 patients consecutively recruited from two tertiary centers (Newcastle cohort: n = 471 and Pisa cohort: n = 266) and a non-COVID control cohort (n = 934). Arterial stiffness was calculated using validated formulae for ePWV. ePWV progressively increased across the control group, COVID-19 survivors and deceased patients (adjusted mean increase per group 1.89 m/s, P < 0.001). Using a machine learning approach, ePWV provided incremental prognostic value and improved reclassification for mortality over the core model including age, sex and comorbidities [AUC (core model + ePWV vs. core model) = 0.864 vs. 0.755]. ePWV provided similar prognostic value when pulse pressure or hs-Troponin were added to the core model or over its components including age and mean blood pressure (p < 0.05 for all). The optimal prognostic ePWV value was 13.0 m/s. ePWV conferred additive discrimination (AUC: 0.817 versus 0.779, P < 0.001) and reclassification value (NRI = 0.381, P < 0.001) over the 4C Mortality score, a validated score for predicting mortality in COVID-19 and the Charlson comorbidity index. We suggest that calculation of ePWV, a readily applicable estimation of arterial stiffness, may serve as an additional clinical tool to refine risk stratification of hospitalized patients with COVID-19 beyond established risk factors and scores.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据